Department of Community Health Management, Baoan District Central Hospital, Shenzhen, People's Republic of China.
Department of Social Medicine and Health Management, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
J Diabetes. 2022 Nov;14(11):767-779. doi: 10.1111/1753-0407.13331.
We evaluated the effects of visit-to-visit variability of systolic blood pressure (SBP) and diastolic blood pressure (DBP) on macrovascular and microvascular complications among patients with type 2 diabetes.
A total of 11 043 patients with type 2 diabetes from primary healthcare institutions between January 2010 and June 2020 were included. The visit-to-visit blood pressure variability was calculated using three metrics: SD, coefficient of variation (CV), and average real variability (ARV), obtained over a 12-month measurement period. The associations of visit-to-visit blood pressure variability with macrovascular and microvascular complications were evaluated using multivariate-adjusted Cox proportional hazards models, and hazard ratio (HR) with 95% confidence interval (CI) were reported.
There were 330 macrovascular events and 542 microvascular events. Compared to those for participants with the lowest quartile of SD of SBP and DBP, increased risks were observed in patients with the highest quartile of SD of SBP and DBP for macrovascular complications (SD-SBP: HR = 1.78, 95% CI: 1.24-2.57; SD-DBP: HR = 2.20, 95% CI: 1.50-3.25) and microvascular complications (SD-SBP: HR = 1.85, 95% CI: 1.39-2.46; SD-DBP: HR = 1.82, 95% CI: 1.36-2.44). CV and ARV of SBP and DBP also had statistically significant associations with macrovascular and microvascular complications. The optimal variability of blood pressure target was SD of SBP <6.45 mm Hg and SD of DBP <4.81 mm Hg.
Visit-to-visit blood pressure variability may be a potential predictor for macrovascular and microvascular complications in patients with type 2 diabetes.
我们评估了收缩压(SBP)和舒张压(DBP)的随访间变异性对 2 型糖尿病患者大血管和微血管并发症的影响。
共纳入 2010 年 1 月至 2020 年 6 月期间来自基层医疗机构的 11043 例 2 型糖尿病患者。在 12 个月的测量期间,使用三个指标(SD、变异系数(CV)和平均真实变异性(ARV))计算随访间血压变异性。使用多变量调整的 Cox 比例风险模型评估随访间血压变异性与大血管和微血管并发症的相关性,并报告风险比(HR)及其 95%置信区间(CI)。
共发生 330 例大血管事件和 542 例微血管事件。与 SBP 和 DBP 的 SD 最低四分位数的参与者相比,SBP 和 DBP 的 SD 最高四分位数的患者发生大血管并发症的风险增加(SD-SBP:HR=1.78,95%CI:1.24-2.57;SD-DBP:HR=2.20,95%CI:1.50-3.25)和微血管并发症(SD-SBP:HR=1.85,95%CI:1.39-2.46;SD-DBP:HR=1.82,95%CI:1.36-2.44)。SBP 和 DBP 的 CV 和 ARV 也与大血管和微血管并发症有统计学显著相关性。血压目标的最佳变异性为 SBP 的 SD<6.45mmHg 和 DBP 的 SD<4.81mmHg。
随访间血压变异性可能是 2 型糖尿病患者大血管和微血管并发症的潜在预测因素。